IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today ...

Presenting new clinical data from Phio's on-going Phase 1b trialMarlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio ...

Patients with mild presbyopia achieve the best near vision outcomes following treatment with CSF-1 — a drop containing 0.4% pilocarpine.

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

at 10:05 Nimbus Therapeutics Presents Positive Updated Data from Phase 1/2 Clinical Trial of HPK1 Inhibitor for Advanced Solid Tumors at SITC 39th Annual Meeting Nimbus Therapeutics, LLC ("Nimbus ...

Third Harmonic Bio, Inc. (NASDSAQ: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory and gastrointestinal inflammatory diseases, ...

Treating stage 1 neurotropic keratopathy treatment with cenegermin ophthalmic solution improves short-term corneal healing.

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in a moment. (Operator Instructions) I'll now hand the ...

VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...

AgenT-797 combined with bispecific engagers targeting antigens such as MUC16, HER2, Claudin 18.2, and DLL3, promote increased ...